News

Panion acquires access to dog study

Panion has made an agreement with Copenhagen University about transfer and use of technical data from a study in dogs. 

The study is conducted by well-reputed researchers and is very relevant for Panion's development of our gene therapy product for dogs with epilepsy. The study is not yet published by the researchers, but Panion may use the data in the contact with FDA and other authorities to speed up the development process from the day the agreement is signed.

"We are very pleased with the agreement, and we expect that this will ease our way to the next trial for our innovative product and to the market" says Anja Holm, CEO of Panion Animal Health.

AUGUST 14 2017

For further information, please contact:
Anja E. H. Holm, VD | + 45-22 94 66 00 
anja.holm@panion-animalhealth.com

This press release contains information which Panion Animal Health AB is obliged to publish according to the EU market abuse regulation (MAR). This information was submitted by Panion's CEO, Anja E. H. Holm, for publication on August 14 2017.

In June 2015 CombiGene formed a wholly owned subsidiary, then called CombiGene Vet linkedin.com/company/panion-animalhealth AB, and in April 2016 the decision was taken to distribute the subsidiary to CombiGe- ne's shareholders with the aim of listing the company. The company, which has been twitter.com/panionanihealth renamed Panion Animal Health AB, will use CombiGene's discoveries to develop a panion-animalhealth.com/newsletter treatment for canine epilepsy. Panion aims at inlicensing or acquiring other veterinary medicine projects or products.

2018-01-19

Panion Animal Health AB's Director Regulatory Affairs, Niels-Erik Manniche, has decided to leave the company.

2018-01-09

Panion Animal Health AB (the "Company") has entered into a financing agreement with New York based Yorkville Advisors Global ("Yorkville") as the investment manager and on behalf of one or more of its investment funds has agreed to purchase up to SEK 9,000,000 of Convertible Notes of Panion Animal Health AB. In addition, Panion has entered into a financing agreement with Dividend Sweden who has agreed to purchase SEK 500,000 of convertible Notes of Panion Animal Health AB.

2018-01-03

Panion Animal Health AB ("Panion") has in Q4-17 requested the FDA to open an Investigational New Animal Drug application file to carry out the development of our new product for use in the dog. Panion plans to develop and gain approval for the use of CG-01-canine, a recombinant adeno-associated virus vector expressing neuropeptide Y and receptor peptide Y2 to treat drug refractory idiopathic epilepsy in the dog via intracranial injection.

2017-12-29

Panion Animal Health AB has had a very satisfactory cooperation with our CFO Anni Acs, who excellently handled the business transition into the stock market, shares issue, and daily financial controlling. Anni has moved to a new job challenge and we wish her all the best.

2017-12-11

Panion Animal Health AB has received the European Medicines Agency's acceptance of the classification as MUMS (Minor Use Minor Species) for our epilepsy product for both dogs and cats. The request for classification was submitted to the Committee for Medicinal Products for Veterinary Use (CVMP) in the European Medicines Agency (EMA) earlier in 2017 and has now been successfully evaluated. 

1
2
...
7
>>

Subscribe

Press releases and reports via E-mail.